Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study
- PMID: 20853113
- DOI: 10.1007/s00415-010-5750-x
Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study
Abstract
Idiopathic intracranial hypertension (IIH) is a disorder of raised intracranial pressure (ICP) in the absence of identifiable pathology. The purpose of this study was to evaluate the clinical presentation and monitor a 3-month course using frequent optical coherence tomography (OCT) evaluations, visual field testings and lumbar opening pressure measurements. A longitudinal study of 17 patients with newly diagnosed IIH and 20 healthy overweight controls were included in the study. Peripapillary retinal nerve fiber layer thickness (RNFLT) and retinal thickness (RT) measurements (Stratus OCT-3, fast RNFL 3.4 protocol), and Humphrey visual field testing were evaluated at regular intervals. Repeat lumbar puncture was performed at final visit (n = 13). The diagnostic delay was 3 months and initial symptoms were headache (94%), visual blurring (82%) and pulsatile tinnitus (65%). Complete clinical remission was achieved in 65%, partial in 29% and unchanged symptoms in 6%. Total average RNFLT and RT decreased significantly during the follow-up period (p < 0.0001 and p < 0.0001, respectively). Changes in RNFLT and RT correlated with improvements in visual field mean deviation (MD) (RNFLT: p = 0.006; RT: p = 0.03) and pattern standard deviation (PSD) (RNFLT: p = 0.002; RT: p = 0.003). In patients with weight-loss >3.5% of BMI, ICP decreased significantly (p = 0.0003). In patients with weight-loss <3.5% of BMI, changes in ICP were insignificant (p = 0.6). OCT combined with visual field testing may be a valuable objective tool to monitor IIH patients and the short term IIH outcome is positive. Weight-loss is the main predictor of a favorable outcome with respect to CSF pressure.
Similar articles
-
Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.Ophthalmology. 2015 Sep;122(9):1939-45.e2. doi: 10.1016/j.ophtha.2015.06.003. Epub 2015 Jul 18. Ophthalmology. 2015. PMID: 26198807 Free PMC article. Clinical Trial.
-
Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension.Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):567-74. doi: 10.1007/s00417-012-2039-z. Epub 2012 May 18. Graefes Arch Clin Exp Ophthalmol. 2013. PMID: 22592348
-
Can Lumbar Puncture Be Safely Deferred in Patients With Mild Presumed Idiopathic Intracranial Hypertension?J Neuroophthalmol. 2022 Dec 1;42(4):505-508. doi: 10.1097/WNO.0000000000001411. Epub 2021 Oct 22. J Neuroophthalmol. 2022. PMID: 34860748
-
Update on Idiopathic Intracranial Hypertension.Neurol Clin. 2017 Feb;35(1):45-57. doi: 10.1016/j.ncl.2016.08.004. Neurol Clin. 2017. PMID: 27886895 Free PMC article. Review.
-
Retinal Manifestations of Idiopathic Intracranial Hypertension.Ophthalmol Retina. 2021 May;5(5):429-437. doi: 10.1016/j.oret.2020.08.016. Epub 2020 Aug 26. Ophthalmol Retina. 2021. PMID: 32860958 Review.
Cited by
-
Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases.J Pain Res. 2016 Apr 19;9:223-32. doi: 10.2147/JPR.S80824. eCollection 2016. J Pain Res. 2016. PMID: 27186074 Free PMC article. Review.
-
Longitudinal visual outcomes in idiopathic intracranial hypertension: the role of early prognostic indicators and risk stratification in disease management.J Neurol. 2025 Jan 15;272(2):108. doi: 10.1007/s00415-024-12859-3. J Neurol. 2025. PMID: 39812855
-
Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.Ophthalmology. 2015 Sep;122(9):1939-45.e2. doi: 10.1016/j.ophtha.2015.06.003. Epub 2015 Jul 18. Ophthalmology. 2015. PMID: 26198807 Free PMC article. Clinical Trial.
-
Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT.PLoS One. 2012;7(5):e36965. doi: 10.1371/journal.pone.0036965. Epub 2012 May 15. PLoS One. 2012. PMID: 22615858 Free PMC article.
-
New-Onset Isolated Asymptomatic Papilledema in Two Patients Treated With Recombinant Growth Hormone.Clin Pediatr (Phila). 2018 Apr;57(4):471-474. doi: 10.1177/0009922817698808. Epub 2017 Mar 22. Clin Pediatr (Phila). 2018. PMID: 28952359 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources